Cognitive Decline in Non-demented PD

Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as
PD progresses. Attention deficits in PD patients with dementia strongly predict the
impairment of their daily living activities.

Previous studies have shown that atomoxetine improves PD executive dysfunction and
rivastigmine improves attention deficits in PD patients with dementia without worsening the
motor symptoms.

The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention
and quality of life in PD patients without disabling cognitive impairment.

Inclusion Criteria:

- Clinical diagnosis of Parkinson's disease

- Respond to levodopa therapy

Exclusion Criteria:

- Dementia

- Psychiatric disorders including anxiety disorders, dissociative disorders, mood
disorders, schizophrenia and related disorders, or ADD/ADHD

- Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver
disease, kidney or renal failure or others that might require hospitalization

- Evidence for another neurological disease (history of seizures, Alzheimer disease,
multiple sclerosis or other movement disorders);

- Currently using any of the study drugs;

- Colorblindness